Temozolomide and Pituitary Tumors : Current Understanding, Unresolved Issues, and Future Directions

ABSTRACT: Temozolomide, an alkylating agent, initially used in the treatment of gliomas was expanded to include pituitary tumors in 2006. After 12 years of use, temozolomide has shown a notable advancement in pituitary tumor treatment with a remarkable improvement rate in the 5-year overall survival...

Full description

Autores:

Syro Moreno, Luis Vicente
Rotondo, Fabio
Camargo Guerrero, Mauricio
Ortíz Gómez, León Darío
Serna Ortíz, Carlos Andrés
Kovacs, Kalman

Tipo de recurso:

Review article

Fecha de publicación:

2018

Institución:

Universidad de Antioquia

Repositorio:

Repositorio UdeA

Idioma:

eng

OAI Identifier:

oai:bibliotecadigital.udea.edu.co:10495/20366

Acceso en línea:

http://hdl.handle.net/10495/20366
https://www.frontiersin.org/articles/10.3389/fendo.2018.00318/full

Palabra clave:

Agentes alquilantes
Alkylating Agents
Antineoplastic Agents
Antineoplásicos
Reparación del ADN
DNA Repair
Neoplasias
Neoplasms
Tumores Neuroendocrinos
Neuroendocrine Tumors
O(6)-Methylguanine-DNA Methyltransferase
O(6)-Metilguanina-ADN Metiltransferasa
Neoplasias Hipofisarias
Pituitary Neoplasms
Temozolomida
Temozolomide
Metiltransferasa
Methyltransferases
Quimioterapia
Chemotherapy

Rights

openAccess

License

http://creativecommons.org/licenses/by/2.5/co/